Product
IMC-C103C
1 clinical trial
1 indication
Indication
solid tumorsClinical trial
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive CancerStatus: Terminated, Estimated PCD: 2023-09-25